OLMA - Olema Pharmaceuticals

-

$undefined

N/A

(N/A)

Olema Pharmaceuticals NasdaqGS:OLMA Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors palbociclib and ribociclib, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, and with an mTOR inhibitor everolimus that is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer. It also develops OP-3136, an orally-available small molecule that potently and selectively inhibits KAT6 for patients with ER+/HER2- metastatic breast cancer and other cancers which is in Phase 1 clinical trial. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Location: 780 Brannan Street, San Francisco, CA, 94103, United States | Website: https://olema.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-69.29M

Cash

392.7M

Avg Qtr Burn

-31.21M

Short % of Float

13.79%

Insider Ownership

3.32%

Institutional Own.

98.86%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
OP-1250 (palazestrant) (CER antagonist) Details
Metastatic breast cancer, Cancer

Phase 3

Data readout

Palazestrant (OP-1250) + ribociclib Details
ER+/HER2- breast cancer, Cancer

Phase 3

Initiation

OP-1250 (palazestrant) + everolimus Details
Metastatic breast cancer, Breast cancer, Cancer

Phase 1/2

Data readout

OP-1250 (palazestrant) +palbociclib Details
Metastatic breast cancer, Breast cancer, Cancer

Phase 1/2

Update

OP-1250 (palazestrant) + ribociclib or alpelisib Details
Breast cancer, Metastatic breast cancer, Cancer

Phase 1/2

Update

OP-3136 Details
Cancer, ER+/HER2- breast cancer

Phase 1

Data readout